1. Home
  2. Search

Search

Search results

373 results found

Natalya Shneyder, MD

Person: Sub-Investigator, Physician, Movement Disorder Specialist
Natalya Shneyder is an Assistant Professor of Neurology at University of South Florida Morsani College of Medicine in Tampa. She serves as a Movement Disorders Specialist at USF Health Byrd Parkinson’s Disease and Movement Disorders Center. Dr. Shneyder earned a medical degree from Zaporizhzhya...

Gabriella Mazur, BS

Person: Clinical Research Associate, Study Coordinator
Gabby Mazur earned her B.S. in Behavioral Neuroscience from Florida State University. During her time at FSU, she served as a Research Assistant at the Anxiety and Behavioral Health Clinic, studying Generalized Anxiety, PTSD, and OC-Spectrum Disorders. After graduation, she transitioned to oncology...

Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.

Publication: Journal Article
Patel, AT, MF Lew, K Dashtipour, S Isaacson, RA Hauser, W Ondo, P Maisonobe, S Wietek, B Rubin, and A Brashear. 2021. “Sustained Functional Benefits After a Single Set of Injections With AbobotulinumtoxinA Using a 2-ML Injection Volume in Adults With Cervical Dystonia: 12-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3b Study.”. ECollection.

Study Investigators. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary? 2023 Mar 22. doi: 10.3233/JPD-223537. 2023;13(3):403-414. PMID: 36970914

Publication: Journal Article
Hauser, RA, WG Ondo, L Zhang, A Bowling, B Navia, E Pappert, and SH Isaacson. 2023. “Study Investigators. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary? 2023 Mar 22. Doi: 10.3233/JPD-223537. 2023;13(3):403-414. PMID: 36970914”. J Parkinsons Dis.

Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search. Parkinsons Dis. 2022 Jun 7;2022:2920255. doi: 10.1155/2022/2920255. eCollection 2022. PMID: 35711334

Publication: Journal Article
Morinan, G, RA Hauser, A Schrag, J Tang, J O’Keeffe, and MDS-NMS Scale Development Study Group. 2022. “Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search. Parkinsons Dis. 2022 Jun 7;2022:2920255. Doi: 10.1155/2022/2920255. ECollection 2022. PMID: 35711334”. Parkinsons Dis.

NINDS NET-PD Investigators. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 2017;7:117-127.

Publication: Journal Article
Hauser, RA, R Li, A Perez, X Ren, D Weintraub, J Elm, JL Goudreau, et al. 2017. “NINDS NET-PD Investigators. Longer Duration of MAO-B Inhibitor Exposure Is Associated With Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 2017;7:117-127.”. J Parkinsons Dis.

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord 2017;32:1335-1336.

Publication: Journal Article
Goetz, CG, GT Stebbins, KA Chung, AP Nicholas, RA Hauser, D Merkitch, and MA Stacy. 2017. “Topiramate As an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study. Mov Disord 2017;32:1335-1336.”. Mov Disord.